Update on Funding Facility and Clinical Program
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Nexalis is currently reassessing its clinical development priorities and plans to revise its development timeline for drug candidates. Additionally, the company received proceeds from a research and development tax incentive following its income tax return.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Nexalis Therapeutics Limited on 6ix
Story so far
Earlier from Nexalis Therapeutics
- Binding Letter of Intent to replace existing $53m facility
- Suspension from Quotation
- Mar26 Appendix 4C Cash Flow Report
- Significant Milestone - First Patient Screened IRX-211 Ph2
- First patient dosed in IRX-616a Phase 1 trial
Later from Nexalis Therapeutics
- Jun26 Appendix 4C Cash Flow Report
- Removal of draft wording in the directors report HY accounts
- Sep26 Quarterly Activities Report
- Sep26 Appendix 4C Cash Flow Report
Follow Nexalis Therapeutics into a list and get an email when it puts out news.
Follow Nexalis Therapeutics